^
    Back
    Association details:
    Biomarker:SHOC2 deletion
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 3081: SHOC2 is a critical modulator of the sensitivity to EGFR-TKI in non-small cell lung cancer cells

    Published date:
    05/15/2020
    Excerpt:
    Additionally, we showed that SHOC2 depletion enhanced the growth inhibitory effect of osimertinib in vivo. Lastly, we confirmed the increased expression of SHOC2 in clinical human samples which experienced EGFR-TKI failure.
    DOI:
    10.1158/1538-7445.AM2020-3081